SCHEMBL7464064

SCHEMBL7464064

CCCCOc1ccc(S(=O)(=O)N[C@H](CN)C(=O)NO)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 5/20 0.57
MMP1 P03956 4/20 0.57
MMP2 P08253 3/20 0.57
MMP14 P50281 2/20 0.57
ADAMTS4 O75173 1/20 0.57
ADAMTS5 Q9UNA0 1/20 0.57
MMP3 P08254 2/20 0.55
ADAM17 P78536 5/20 0.52
MMP9 P14780 4/20 0.52
KCNA5 P22460 2/20 0.50
ADAM10 O14672 2/20 0.49
ADAM8 P78325 2/20 0.49
MMP12 P39900 1/20 0.49
LMNA P02545 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA9 Q16790 2/20 0.49
TSHR P16473 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7411093 0.90 MMP13 (0.60) MMP13MMP1MMP2MMP14ADAMTS4
SCHEMBL7413161 0.89 MMP2 (0.53) MMP13MMP1MMP2MMP14ADAMTS4
SCHEMBL31086993 0.88 MMP13 (0.57) MMP13MMP1MMP2MMP14ADAMTS4
SCHEMBL7417303 0.86 MMP1 (0.68) MMP13MMP1MMP2MMP14ADAMTS4
SCHEMBL7461414 0.85 MMP13 (0.56) MMP13MMP1MMP2MMP3ADAM17
SCHEMBL7419743 0.84 MMP2 (0.69) MMP13MMP1MMP2MMP14ADAMTS4
SCHEMBL7420442 0.81 MMP1 (0.69) MMP13MMP1MMP2MMP14ADAMTS4
SCHEMBL4921260 0.81 MMP9 (0.51) MMP13MMP1MMP2MMP14ADAM17
SCHEMBL4921267 0.81 MMP9 (0.51) MMP13MMP1MMP2MMP14ADAM17
SCHEMBL2513418 0.81 MMP13 (0.50) MMP13MMP1MMP2MMP14ADAMTS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218389-B1 FOR THERAPY AND PROPHYLAXIS OF ARTHRITIS, CANCER, CARDIOVASCULAR DISORDERS; SKIN DISORDERS; OCULAR DISORDERS; INFLAMMATION AND GUM DISEASES, MULTIPLE SCLEROSIS, CACHEXIA, PREVENTING LOOSENING OF PROSTHETIC DEVICES THE PROCTER & GAMBLE CO. 2001-04-17 US disclosed
EP-1009737-A2 SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2000-06-21 EP disclosed
WO-1999006340-A2 SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 1999-02-11 WO disclosed